Literature DB >> 10497982

A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996.

R R Graham1, M Juffrie, R Tan, C G Hayes, I Laksono, C Ma'roef, K R Porter, S B Halstead.   

Abstract

A prospective study on dengue (DEN) viruses was initiated in October 1995 in Gondokusuman kecamatan, Yogyakarta, Indonesia. This report presents data from the first year of the study. The studied cohort included all children 4-9 years of age living in the kecamatan. Blood samples for serology were collected from 1,837 children in October 1995 and again in October 1996. Blood samples for virus isolation and serology were collected from cohort children who were seen in municipal health clinics with febrile syndromes or admitted to hospitals with a provisional diagnosis of dengue hemorrhagic fever. Dengue serotype antibody prevalence and 1995-1996 infection rates were calculated using a single dilution (1:60) 70% plaque reduction endpoint neutralization test. Prevalence of dengue antibody at the beginning of the study was DEN 1 = 12%, DEN 2 = 16%, DEN 3 = 2%, DEN 4 = 4%, and two or more dengue infections = 22%. Total dengue antibody prevalence increased from 38% in 4-year-old children to 69% in 9-year-old children. During the observation period, primary dengue infection rates were DEN 1 = 4.8%, DEN 2 = 7.7%, DEN 3 = 4.2%, and DEN 4 = 3.4%, while two or more dengue infections occurred in 6.7% of the study population. The secondary dengue infection rate was 19.0%. From febrile cases, all four dengue viruses were isolated with DEN 3 predominating. Seven children were hospitalized, including one fatal case with a hospital diagnosis of dengue shock syndrome. Based upon presence of antibody in the initial cohort bleeding and the serologic response both weeks and several months following illness, all had secondary dengue infections. Neutralizing antibody patterns in the initial cohort bleeding and in late convalescent serum samples permitted recognition of dengue infection sequence in five patients: DEN 2-DEN 1 (3), DEN 2-DEN 4 (1), DEN 1-DEN 3 (1), and none in the sequence DEN 1-DEN 2. In the total cohort 6.5% of the observed secondary infections were of the sequence DEN 2-DEN 1, while 4.9% were DEN 1-DEN 2, a highly pathogenic sequence in previous studies. Reduced pathogenic expression of secondary DEN 2 with enhanced pathogenic expression of secondary DEN 1 infections was an unexpected finding. Further studies will be required to understand the respective contributions to pathogenicity of antibody from initial dengue infections versus the biological attributes of the second infecting dengue viruses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497982     DOI: 10.4269/ajtmh.1999.61.412

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  81 in total

1.  Factors associated with dengue mortality in Latin America and the Caribbean, 1995-2009: an ecological study.

Authors:  Fredi Alexander Díaz-Quijano; Eliseu Alves Waldman
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  A three-component biomarker panel for prediction of dengue hemorrhagic fever.

Authors:  Allan R Brasier; Hyunsu Ju; Josefina Garcia; Heidi M Spratt; Sundar S Victor; Brett M Forshey; Eric S Halsey; Guillermo Comach; Gloria Sierra; Patrick J Blair; Claudio Rocha; Amy C Morrison; Thomas W Scott; Isabel Bazan; Tadeusz J Kochel
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

3.  Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections.

Authors:  Cameron P Simmons; Tao Dong; Nguyen Vinh Chau; Nguyen Thi Phuong Dung; Tran Nguyen Bich Chau; Le Thi Thu Thao; Nguyen Thi Dung; Tran Tinh Hien; Sarah Rowland-Jones; Jeremy Farrar
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  The epidemiology of dengue in the americas over the last three decades: a worrisome reality.

Authors:  José Luis San Martín; Olivia Brathwaite; Betzana Zambrano; José Orlando Solórzano; Alain Bouckenooghe; Gustavo H Dayan; María G Guzmán
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

5.  Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection.

Authors:  Steven Hatch; Tim P Endy; Stephen Thomas; Anuja Mathew; James Potts; Pamela Pazoles; Daniel H Libraty; Robert Gibbons; Alan L Rothman
Journal:  J Infect Dis       Date:  2011-02-18       Impact factor: 5.226

Review 6.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

7.  Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006.

Authors:  Jessica R Fried; Robert V Gibbons; Siripen Kalayanarooj; Stephen J Thomas; Anon Srikiatkhachorn; In-Kyu Yoon; Richard G Jarman; Sharone Green; Alan L Rothman; Derek A T Cummings
Journal:  PLoS Negl Trop Dis       Date:  2010-03-02

8.  Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission.

Authors:  Amy C Morrison; Sharon L Minnick; Claudio Rocha; Brett M Forshey; Steven T Stoddard; Arthur Getis; Dana A Focks; Kevin L Russell; James G Olson; Patrick J Blair; Douglas M Watts; Moises Sihuincha; Thomas W Scott; Tadeusz J Kochel
Journal:  PLoS Negl Trop Dis       Date:  2010-05-04

9.  Clinical and virological features of Dengue in Vietnamese infants.

Authors:  Tran Nguyen Bich Chau; Katherine L Anders; Le Bich Lien; Nguyen Thanh Hung; Lu Thi Minh Hieu; Nguyen Minh Tuan; Tran Thi Thuy; Le Thi Phuong; Nguyen Thi Hong Tham; Mai Ngoc Lanh; Jeremy J Farrar; Stephen S Whitehead; Cameron P Simmons
Journal:  PLoS Negl Trop Dis       Date:  2010-04-13

10.  Age and clinical dengue illness.

Authors:  Joseph R Egger; Paul G Coleman
Journal:  Emerg Infect Dis       Date:  2007-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.